Bayer Aktiengesellschaft (BAYZF)
OTCMKTS · Delayed Price · Currency is USD
44.48
-0.45 (-1.00%)
Jan 6, 2026, 4:00 PM EST
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B EUR
Revenue Growth
-1.87%
P/S Ratio
0.81
Revenue / Employee
499.28K EUR
Employees
91,864
Market Cap
43.68B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Bayer Aktiengesellschaft News
- 1 day ago - Bayer sues COVID vaccine makers over mRNA technology - Reuters
- 1 day ago - Pesticide industry ‘immunity shield’ stripped from US appropriations bill - The Guardian
- 2 days ago - Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan's 44th Annual Healthcare Conference - Business Wire
- 7 days ago - BAYRY's 2025 Revival: Will the Momentum Continue in 2026? - Nasdaq
- 25 days ago - Bayer: Is This The Turning Point Investors Have Been Waiting For? - Seeking Alpha
- 27 days ago - DCM Shriram shares rally sharply 6% as company signs strategic MoU with Bayer to boost agri-innovation - Business Upturn
- 4 weeks ago - DCM Shriram and Bayer Crop Science sign strategic MoU to advance sustainable agriculture in India - Business Upturn
- 4 weeks ago - Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome - Business Wire